Cord Blood-derived CAR NK Cells Targeting CD19/CD70(Shanghai Tongji Hospital)

N/A

Report date: 2024/07/23 15:22:51

Base Information

Drug NameCord Blood-derived CAR NK Cells Targeting CD19/CD70(Shanghai Tongji Hospital)
Drug Alias NamedualCAR-NK19/70 cell(Tongji University)dualCAR-NK19/70(Shanghai Tongji Hospital)dualCAR-NK19/70 cell(Shanghai Tongji Hospital)
ClassificationCell and gene therapy > Cell therapy > Source of cells > Umbilical cord blood-derivedCell and gene therapy > Cell therapy > Immune system cell therapy > Cytokine-induced killer cell > Chimeric antigen receptor CIK cell therapy
Mechanisms of ActionAnti-CD19Anti-CD70
TargetsB-lymphocyte antigen CD19CD70 antigen
Therapy Area/IndicationsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai Tongji Hospital
China Registration ClassN/A

Develop Information

Active CompaniesTongji UniversityShanghai Tongji Hospital
Inactive CompaniesN/A
Active IndicationsLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A